Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer

References

• Singapore Cancer Registry, National registry of diseases office. Singapore cancer registry 50th anniversary monograph (1968-2017). Available from: https://www.nrdo.gov.sg/publications/cancer
   Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, et al. Latest research and clinical treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10:211–224.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384:1376–1388.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Lynparza tablet prescribing information; [cited 2020 Sep 22]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
   Google Scholar
• Singapore Health Sciences Authority. Lynparza tablet package insert; [cited 2020 Sep 22]. Available from: https://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProduct.do?action=load
   Google Scholar
• Friedlander M, Matulonis U, Gourley C, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018;119:1075–1085.
   PubMed Web of Science ®Google Scholar
• Pearce F, Lin L, Teo E, et al. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183.
   PubMedGoogle Scholar
• Drug Evaluation Methods and Process Guide. Agency for care effectiveness. Singapore: Ministry of Health; [December 2019]. Available from: https://www.ace-hta.gov.sg.
   Google Scholar
• Abiraterone for treating metastatic prostate cancer. Technology guidance. Agency for care effectiveness. Singapore: Ministry of Health; [2020 Oct 1]. Available from https://www.ace-hta.gov.sg.
   Google Scholar
• Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia. Technology guidance. Agency for care effectiveness. Singapore: Ministry of Health; 2020 Sep 1; [cited 2020 Sep 22]. Available from: https://www.ace-hta.gov.sg
   Google Scholar
• Secord AA, Barnett JC, Ledermann JA, et al. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer. 2013;23:846–852.
   PubMed Web of Science ®Google Scholar
• Dottino JA, Moss HA, Lu KH, et al. U.S. food and drug administration–approved poly (ADP-ribose) polymerase inhibitor maintenance therapy for recurrent ovarian cancer: a cost-effectiveness analysis. Obstet Gynecol. 2019;133:795–802.
   PubMed Web of Science ®Google Scholar
• Zhong L, Tran AT, Tomasino T, et al., Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer. J Manag Care Spec Pharm. 2018;24(12): 1219–1228.
   PubMed Web of Science ®Google Scholar
• Woods B, Sideris E, Palmer S, et al. NICE DSU Technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review 2017; [cited 2020 Sep 22]. Available from: www.nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf
   Google Scholar
• Hollis RL, Churchman M, Gourley C. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther. 2017;10:2539–2551.
   PubMed Web of Science ®Google Scholar
• Aziz MIA, Tan LE, Tan WHG, et al. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. J Med Econ. 2020;23:952–960.
   Web of Science ®Google Scholar
• Phua LC, Lee SC, Ng K, et al. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020;20:581.
   PubMed Web of Science ®Google Scholar
• Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13:255–261.
   PubMed Web of Science ®Google Scholar
• Cress RD, Chen YS, Morris CR, et al. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126(3):491–497.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–1284.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotDigitizer (version 4.2, April 2019) San Francisco, California, USA; [cited 2020 Sep 22]. Available from: https://automeris.io/WebPlotDigitizer
   Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11(1):139.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Department of Statistics Singapore: age-specific death rates, annual. 2019; [cited 2020 Sep 22]. Available from: https://www.tablebuilder.singstat.gov.sg/publicfacing/mainMenu.action
   Google Scholar
• Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19:1126–1134.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer: technology appraisal guidance [TA620]. 15 Jan 2020; [cited 2020 Sep 22]. Available from: https://www.nice.org.uk/guidance/ta620
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer: NICE appraisal consultation committee papers [ID1296]. 15 Jan 2020; [cited 2020 Sep 22]. Available from: https://www.nice.org.uk/guidance/ta620/evidence
   Google Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer, Version 1.2020, Mar 11 2020; [cited 2020 Sep 22]. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#site
   Google Scholar
• Madariaga A, Lheureux S, Oza AM. Tailoring ovarian cancer treatment: implications of BRCA1/2 mutations. Cancers (Basel). 2019;11:416.
   Web of Science ®Google Scholar
• Strom CM, Rivera S, Elzinga C, et al. Development and validation of a next-generation sequencing assay for BRCA1 and BRCA2 variants for the clinical laboratory. PLoS ONE. 2015;10(8):e0136419.
   PubMed Web of Science ®Google Scholar
• Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.
   PubMed Web of Science ®Google Scholar
• Digital Signal PM Processing 101: everything you need to know to get started. Elsevier Inc, 2017; [cited 2020 Sep 22]. www.sciencedirect.com/topics/engineering/cholesky-decomposition
   Google Scholar
• Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol. 2019;11:1–18.
   Web of Science ®Google Scholar
• Smith HJ, Walters Haygood CL, Arend RC, et al. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2015;139(1): 59–62.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Poly ADP-ribose polymerase (PARP) inhibitors for ovarian cancer: effectiveness and value – final evidence report. 28 Sep 2017; [cited 2020 Sep 22]. Available from: https://icer-review.org/material/ovarian-cancer-final-report/
   Google Scholar
• Tappenden P, Harnan S, Ren S, et al. Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2017;35:97–109.
   PubMed Web of Science ®Google Scholar
• Guy H, Walder L, Fisher M. Cost‑effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the United States. PharmacoEconomics. 2019;37:391–405.
   PubMed Web of Science ®Google Scholar
• Eccleston A, Bentley A, Dyer M, et al. A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer. Value Health. 2017;20:567–576.
   PubMed Web of Science ®Google Scholar
• Moya-Alarcon C, Gonzalez-Dominguez A, Simon S, et al. Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clin Transl Oncol. 2019;21:1076–1084.
   PubMed Web of Science ®Google Scholar